Literature DB >> 22833080

Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma.

Elisabetta Kuhn1, Robert J Kurman, Ann Smith Sehdev, Ie-Ming Shih.   

Abstract

There is mounting evidence that serous tubal intraepithelial carcinoma (STIC) may be the immediate precursor of ovarian high-grade serous carcinoma (HGSC) but the criteria for its diagnosis are not well established as highlighted in a recent study showing that interobserver reproducibility, even among expert gynecologic pathologists, was moderate at best. Given the clinical significance of a diagnosis of STIC in a patient who has no other evidence of ovarian carcinoma, this is a serious issue that we felt needed to be addressed. Although it is not clear, at this time, whether such a patient should or should not be treated, the importance of an accurate and reproducible diagnosis of precursors of ovarian carcinoma cannot be underestimated. We hypothesized that an elevated Ki-67 labeling index may aid the diagnosis of STIC. Accordingly, we compared the Ki-67 index of STIC and HGSC to normal fallopian tube epithelium (FTE) in the same patients and to a control group of patients without carcinoma, matched for age. A total of 41 STICs were analyzed, of which 35 were associated with a concurrent HGSC. In FTE, immunoreactivity for Ki-67 was restricted to a few scattered cells (mean 2.0%). No statistically significant difference was found between patients with and without HGSC (P>0.05). However, both STICs and HGSC had significantly higher Ki-67 indices than normal FTE (P<0.0001). STICs uniformly had an elevated Ki-67 labeling index that ranged from 11.7% to 71.1% (average 35.6%). There was no correlation of the Ki-67 labeling index in the STICs and the associated HGSC, as the labeling index was lower in STIC in 18/35 (51.4%) whereas it was higher in 17/35 (48.6%) (P=0.86). In conclusion, the findings in this study indicate that compared with FTE, STICs have a significantly higher Ki-67 index similar to HGSC. Accordingly, the Ki-67 index can aid the diagnosis of intraepithelial tubal proliferations suspicious for STIC. Therefore, we propose that a Ki-67 index of 10% is a useful diagnostic tool to distinguish STICs from normal FTE.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22833080      PMCID: PMC3715095          DOI: 10.1097/PGP.0b013e31824cbeb4

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  14 in total

1.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

2.  The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

Authors:  Fabiola Medeiros; Michael G Muto; Yonghee Lee; Julia A Elvin; Michael J Callahan; Colleen Feltmate; Judy E Garber; Daniel W Cramer; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2006-02       Impact factor: 6.394

3.  The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

4.  Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study.

Authors:  Kala Visvanathan; Russell Vang; Patricia Shaw; Amy Gross; Robert Soslow; Vinita Parkash; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2011-12       Impact factor: 6.394

5.  Ovarian Cancer Is an Imported Disease: Fact or Fiction?

Authors:  Elisabetta Kuhn; Robert J Kurman; Ie-Ming Shih
Journal:  Curr Obstet Gynecol Rep       Date:  2012-03

6.  Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications.

Authors:  Joseph W Carlson; Elke A Jarboe; David Kindelberger; Marisa R Nucci; Michelle S Hirsch; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2010-07       Impact factor: 2.762

Review 7.  Precursors to pelvic serous carcinoma and their clinical implications.

Authors:  Ann K Folkins; Elke A Jarboe; Michael H Roh; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2009-02-23       Impact factor: 5.482

8.  Serous carcinogenesis in the fallopian tube: a descriptive classification.

Authors:  Elke Jarboe; Ann Folkins; Marisa R Nucci; David Kindelberger; Ronny Drapkin; Alexander Miron; Yonghee Lee; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2008-01       Impact factor: 2.762

9.  Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase.

Authors:  Ann Smith Sehdev; Robert J Kurman; Elisabetta Kuhn; Ie-Ming Shih
Journal:  Mod Pathol       Date:  2010-03-12       Impact factor: 7.842

10.  Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.

Authors:  Amy L Gross; Robert J Kurman; Russell Vang; Ie-Ming Shih; Kala Visvanathan
Journal:  J Oncol       Date:  2010-04-27       Impact factor: 4.375

View more
  18 in total

1.  The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma.

Authors:  Elisabetta Kuhn; Robert J Kurman; Robert A Soslow; Guangming Han; Ann Smith Sehdev; Patrick J Morin; Tian-Li Wang; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

2.  An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.

Authors:  Marie E Perrone; Nicholas P Reder; Sergay N Agoff; Rochelle L Garcia; Kathy J Agnew; Barbara M Norquist; Kathryn P Pennington; Elizabeth M Swisher; Mark R Kilgore
Journal:  Int J Gynecol Pathol       Date:  2020-05       Impact factor: 2.762

Review 3.  The role of the fallopian tube in the origin of ovarian cancer.

Authors:  Britt K Erickson; Michael G Conner; Charles N Landen
Journal:  Am J Obstet Gynecol       Date:  2013-04-10       Impact factor: 8.661

Review 4.  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Authors:  Mark E Sherman; Ronny I Drapkin; Neil S Horowitz; Christopher P Crum; Sue Friedman; Janice S Kwon; Douglas A Levine; Ie-Ming Shih; Donna Shoupe; Elizabeth M Swisher; Joan Walker; Britton Trabert; Mark H Greene; Goli Samimi; Sarah M Temkin; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-24

5.  Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer.

Authors:  Shiho Asaka; Christine Davis; Shiou-Fu Lin; Tian-Li Wang; Christopher M Heaphy; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2019-08       Impact factor: 6.394

6.  The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis.

Authors:  Elisabetta Kuhn; Ayse Ayhan; Ie-Ming Shih; Jeffrey D Seidman; Robert J Kurman
Journal:  Mod Pathol       Date:  2013-07-26       Impact factor: 7.842

7.  Steroid hormone synthesis by the ovarian stroma surrounding epithelial ovarian tumors: a potential mechanism in ovarian tumorigenesis.

Authors:  Luis Z Blanco; Elisabetta Kuhn; Jane C Morrison; Asli Bahadirli-Talbott; Anne Smith-Sehdev; Robert J Kurman
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

8.  Diagnostic implications of Ki-67 expression in adipocytes and lipoblasts: an immunohistochemical study.

Authors:  Hong-Jun Wang; Cong-Yang Li; Yang-Kun Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

9.  Pathologic Classification of Ovarian Cancer.

Authors:  Stephanie M McGregor
Journal:  Methods Mol Biol       Date:  2022

Review 10.  Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.

Authors:  Lana E Kandalaft; Denarda Dangaj Laniti; George Coukos
Journal:  Nat Rev Cancer       Date:  2022-09-15       Impact factor: 69.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.